This company is no longer active
Vallon Pharmaceuticals (VLON) Stock Overview
As of April 21, 2023, Vallon Pharmaceuticals, Inc. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
VLON Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Vallon Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.40 |
| 52 Week High | US$2.17 |
| 52 Week Low | US$0.21 |
| Beta | -1.15 |
| 1 Month Change | -0.52% |
| 3 Month Change | 39.13% |
| 1 Year Change | -82.38% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -94.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| VLON | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 10.5% | -3.0% | -0.2% |
| 1Y | -82.4% | 45.8% | 14.8% |
Return vs Industry: VLON underperformed the US Pharmaceuticals industry which returned 2.6% over the past year.
Return vs Market: VLON underperformed the US Market which returned -5.3% over the past year.
Price Volatility
| VLON volatility | |
|---|---|
| VLON Average Weekly Movement | 42.9% |
| Pharmaceuticals Industry Average Movement | 8.8% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: VLON's share price has been volatile over the past 3 months.
Volatility Over Time: VLON's weekly volatility has increased from 29% to 43% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 2 | n/a | www.vallon-pharma.com |
As of April 21, 2023, Vallon Pharmaceuticals, Inc. was acquired by GRI Bio, Inc., in a reverse merger transaction. Vallon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. The company’s lead investigational product candidate is ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy.
Vallon Pharmaceuticals, Inc. Fundamentals Summary
| VLON fundamental statistics | |
|---|---|
| Market cap | US$5.39m |
| Earnings (TTM) | -US$7.02m |
| Revenue (TTM) | n/a |
Is VLON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VLON income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.02m |
| Earnings | -US$7.02m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did VLON perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/23 20:45 |
| End of Day Share Price | 2023/04/21 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vallon Pharmaceuticals, Inc. is covered by 1 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |